ABIGAIL OWUNNA: Open Payments
NPI 1922597699 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,579 in 36 payments from 22 companies in 2025. Trend: 2023 $1,596 · 2024 $692 · 2025 $1,579
Food & beverage: $1,558Consulting: $21
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $228 |
| Amgen Inc. | 2 | $150 |
| Eisai Inc. | 2 | $141 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $126 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $125 |
| TG Therapeutics, Inc. | 1 | $121 |
| Alnylam Pharmaceuticals Inc. | 1 | $103 |
| CSL Behring | 3 | $99 |
| Genentech USA, Inc. | 3 | $86 |
| GlaxoSmithKline, LLC. | 4 | $77 |
Products named: FASENRA, Leqembi, KRYSTEXXA, ILUMYA, BRIUMVI, AMVUTTRA, Hizentra, Ocrevus Zunovo.
Industry payments across TX — which companies pay providers there.
